Published in The New England Journal of Medicine and presented at the American College of Cardiology’s scientific meeting, “Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation” positions left atrial appendage closure as a viable first-line alternative to long-term oral anticoagulation in eligible patients with nonvalvular atrial fibrillation (A-fib). This publication is a conclusion to…
Norton Children’s Neuroscience Institute, affiliated with UofL School of Medicine, is one of only three sites in the United States selected to participate in the TETRIS study, a clinical trial examining how remote patient monitoring can help clinicians better optimize treatment in patients diagnosed with some severe types of epilepsy. About the clinical trial The…
A major new study shows that individualized treatment for babies born with opioid withdrawal can speed recovery and reduce time spent in the hospital. The clinical trial, led by Lori A. Devlin, D.O., neonatologist with Norton Children’s and a professor in the University of Louisville School of Medicine Department of Pediatrics, found a customized approach…
Norton Children’s Research Institute, affiliated with UofL School of Medicine has appointed Jamie M. Furlong-Dillard, D.O., as its new chief scientific officer, effective July 1. Dr. Furlong-Dillard is a pediatric critical care physician with Norton Children’s Critical Care and an associate professor at the UofL School of Medicine, and has nationally recognized expertise in extracorporeal…
Norton Children’s is currently enrolling neonatal intensive care unit (NICU) patients in a clinical trial evaluating RLS-0071, an investigational novel peptide being studied as a treatment for hypoxic-ischemic encephalopathy (HIE) in newborns. If proven effective, it would be the first pharmacological treatment approved for the condition. The trial represents a collaboration between Norton Children’s Neonatology…
When the diagnosis is stage 4: How Norton Cancer Institute is meeting ovarian cancer’s most aggressive presentations A patient’s journey through advanced ovarian cancer underscores the value of coordinated oncology care, clinical trial access and multidisciplinary expertise close to home. For the referring physician, few moments are as difficult as relaying a Stage 4 ovarian…
Norton Heart & Vascular Institute has joined a select group of North American centers in a landmark randomized clinical trial aimed at reducing one of cardiac surgery’s most common and consequential complications: postoperative atrial fibrillation (POAF). About the trial Postoperative atrial fibrillation affects more than half of patients undergoing cardiac surgery, depending on individual risk…
Norton Heart & Vascular Institute continues to expand its role in advancing cardiovascular clinical research, joining a global clinical trial that potentially could redefine treatment for one of heart failure’s most challenging patient populations: heart failure with preserved ejection fraction, or HFpEF. Why it matters HFpEF patients retain normal left ventricular pumping function (LVEF ≥50%)…
What your patients eat may shape who they become A landmark study published in JAMA Network Open is giving pediatric providers new clinical ammunition for conversations about early childhood nutrition — and the findings go well beyond waistlines. Studies on the link between processed food and behavior have been around for a while and evaluate…
Reviewed by Bassel Alkhalil, M.D., Norton Heart & Vascular Institute Norton Heart & Vascular Institute has been selected as one of only two sites in Kentucky to participate in TEAM-HF, a pioneering clinical trial that could fundamentally change how advanced heart failure is treated. The study, sponsored by Abbott and led locally by principal investigator…
Norton Cancer Institute has added significant clinical oncology research expertise with the arrival of Kevin T. Breen, M.D., Ph.D., who is expected to become one of the new leaders of Norton Cancer Institute’s early-phase clinical trials program. Dr. Breen brings specialized knowledge in brain cancer immunotherapy from his previous work at the National Institutes of…
A groundbreaking clinical trial at Norton Cancer Institute is exploring whether CAR T-cell therapy —a cellular therapy originally developed to treat cancer — could provide a curative treatment for patients with severe autoimmune diseases, including systemic lupus erythematosus (SLE), myositis and scleroderma. The RESOLUTION trial, led by principal investigator Don A. Stevens, M.D., hematologist/oncologist with…